Author

R. Imle

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Assay:bulk RNA-seq· 4 Organism:human· 4 Research Focus:differential expression· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

A. Banito· 5 shared F. Cidre-Aranaz· 4 shared C. M. Funk· 3 shared H. Peterziel· 3 shared I. Oehme· 3 shared J. Li· 3 shared S. Ohmura· 3 shared T. G. P. Gruenewald· 3 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

A. Banito

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Glutaredoxin 3 (GLRX3) confers a fusion oncogene-dependent vulnerability to Ewing sarcoma

E. Vinca, A. C. Ehlers, A. Ritter, D. Obermeier, C. M. Funk, F. H. Geyer, M. Schmucker, J. Li, M. Zimmermann, A. K. Ceranski, F. Fuchslocher, C. Mertens, R. Qiu, M. M. Muckenthaler, A. Dahlhaus, , S. Ohmura

This study identifies GLRX3 as a vulnerability in Ewing sarcoma driven by EWSR1::FLI1 fusion oncoproteins, showing its role in oxidative stress and iron homeostasis and potential therapeutic targeting.

bioRxiv · Apr 24, 2024 · PreprintCancer Biology

Somatic gene delivery for flexible in vivo modeling of high-risk sarcoma

R. Imle, D. Blosel, F. Kommoss, E. Zhao, R. Autry, C. Blume, D. Lupar, L. Schmitt, C. Winter, L. Wagner, S. Placke, M. von Eicke, M. Hertwig, H. Peterziel, I. Oehme, , A. Banito

This paper develops a mouse model for high-risk sarcoma by delivering genetic lesions via electroporation, generating multiple sarcoma types and validating their molecular and therapeutic relevance.

bioRxiv · Jan 30, 2024 · PreprintCancer Biology

Multidimensional Characterization of Soft-Tissue Sarcomas with FUS-TFCP2 or EWSR1-TFCP2 Fusions

J. Schopf, S. Uhrig, C. E. Heilig, K.-S. Lee, T. Walther, A. Carazzato, A. M. Dobberkau, D. Weichenhan, C. Plass, M. Hartmann, G. D. Diwan, Z. Carrero, C. R. Ball, T. Hohl, T. Kindler, , C. Scholl

This study characterizes soft-tissue sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusions through multi-omics analyses and functional studies, identifying therapeutic targets and mechanisms of disease.

bioRxiv · Feb 19, 2023Cancer Biology

Chromosome 8 gain drives cancer progression by hijacking the translation factor 4E-BP1 sensitizing for targeted CDK4/6 inhibition

C. M. Funk, A. Ehlers, M. F. Orth, K. Aljakouch, J. Li, T. L. B. Hoelting, R. Will, A. K. Ceranski, F. Willis, E. Vinca, S. Ohmura, R. Imle, J. Siebenlist, A. Yershova, M. M. L. Knott, , J. Musa

This study identifies chr8 gains and 4E-BP1 expression as prognostic markers in Ewing sarcoma, showing they drive cancer progression by promoting proliferation and sensitizing to CDK4/6 inhibitors.

bioRxiv · Dec 11, 2022 · PreprintCancer Biology

Systems biology analysis identifies TCF7L1 as a key regulator of metastasis in Ewing sarcoma

F. Cidre-Aranaz, J. Li, T. L. B. Hoelting, M. F. Orth, R. Imle, S. Kutschmann, G. Ammirati, K. Ceranski, M. J. Carreno-Gonzalez, M. Kasan, A. Marchetto, C. M. Funk, F. Bestvater, S. Bersini, C. Arrigoni, , T. G. P. Gruenewald

bioRxiv · Feb 25, 2021 · PreprintCancer Biology